CA3233673A1 - Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity - Google Patents

Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity Download PDF

Info

Publication number
CA3233673A1
CA3233673A1 CA3233673A CA3233673A CA3233673A1 CA 3233673 A1 CA3233673 A1 CA 3233673A1 CA 3233673 A CA3233673 A CA 3233673A CA 3233673 A CA3233673 A CA 3233673A CA 3233673 A1 CA3233673 A1 CA 3233673A1
Authority
CA
Canada
Prior art keywords
compound
occurrence
mixture
mmol
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3233673A
Other languages
English (en)
French (fr)
Inventor
Hongjian Zhang
Ping Chen
Fei Jiang
Peihua Sun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viva Star Biosciences Suzhou Co Ltd
Original Assignee
Viva Star Biosciences Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viva Star Biosciences Suzhou Co Ltd filed Critical Viva Star Biosciences Suzhou Co Ltd
Publication of CA3233673A1 publication Critical patent/CA3233673A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3233673A 2021-09-29 2022-09-27 Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity Pending CA3233673A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2021121548 2021-09-29
CNPCT/CN2021/121548 2021-09-29
PCT/US2022/077120 WO2023056264A1 (en) 2021-09-29 2022-09-27 Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity

Publications (1)

Publication Number Publication Date
CA3233673A1 true CA3233673A1 (en) 2023-04-06

Family

ID=84329267

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3233673A Pending CA3233673A1 (en) 2021-09-29 2022-09-27 Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity

Country Status (10)

Country Link
US (1) US20240400561A1 (enExample)
EP (1) EP4408843A1 (enExample)
JP (1) JP2024538602A (enExample)
KR (1) KR20240089127A (enExample)
CN (1) CN118251393A (enExample)
AU (1) AU2022356377A1 (enExample)
CA (1) CA3233673A1 (enExample)
IL (1) IL311784A (enExample)
MX (1) MX2024003948A (enExample)
WO (1) WO2023056264A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
KR102669722B1 (ko) * 2017-07-07 2024-05-29 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
SG11202001164SA (en) * 2017-08-15 2020-03-30 Inflazome Ltd Novel sulfonamide carboxamide compounds
TW201910316A (zh) * 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
TW201910317A (zh) * 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
PE20210050A1 (es) * 2017-11-09 2021-01-08 Inflazome Ltd Nuevos compuestos de sulfonamida carboxamida
GB201902327D0 (en) * 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds

Also Published As

Publication number Publication date
AU2022356377A1 (en) 2024-04-11
WO2023056264A1 (en) 2023-04-06
US20240400561A1 (en) 2024-12-05
MX2024003948A (es) 2024-06-28
CN118251393A (zh) 2024-06-25
KR20240089127A (ko) 2024-06-20
IL311784A (en) 2024-05-01
EP4408843A1 (en) 2024-08-07
JP2024538602A (ja) 2024-10-23

Similar Documents

Publication Publication Date Title
JP7508584B2 (ja) ＰＩ３Ｋα阻害剤およびそれらの使用
CA3229539A1 (en) Inhibitors of nlrp3
CA3016182C (en) Substituted indole mcl-1 inhibitors
CA2930414C (en) Tetrahydroquinoline compositions as bet bromodomain inhibitors
CA2979391C (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
ES2450568T3 (es) Compuestos espiero de amino-dihidrooxazina y amino-dihidrotiazina como moduladores de beta-secretasa y su uso médico
CA3047336A1 (en) Chemical compounds as inhibitors of interleukin-1 activity
EP4129996A1 (en) Novel aminopyrimidine egfr inhibitor
JP2015025014A (ja) キナーゼ阻害剤として有用な２−アミノピリジン誘導体
CN113454082B (zh) 咪唑并吡啶基化合物及其用于治疗神经退行性疾病的用途
CA3033461A1 (en) Heterocyclic compounds as inhibitors of gcn2
CA2731432A1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
CA2916468A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
MX2011011653A (es) Pirazolopiridinas.
CA2654410A1 (en) Inhibitors of janus kinases
CA3095568A1 (en) Heterocyclic compound
CN119487006A (zh) 作为pge2受体拮抗剂的酰胺化合物
CA3074059A1 (en) Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists
WO2023056264A1 (en) Novel substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
IL298397A (en) Competitive and noncompetitive inhibitors of the muscarinic acetylcholine receptor m5
US12338255B2 (en) Bicyclic substituted sulfonylurea compounds as inhibitors of interleukin-1 activity
HK40107097A (zh) 作为白介素-1活性抑制剂的新型经取代的磺酰脲化合物
EA053340B1 (ru) Гетероциклические ингибиторы glut9 для лечения заболевания
EA052733B1 (ru) Ингибиторы nlrp3
JP2025502100A (ja) 疾患の治療のためのｇｌｕｔ９の複素環式阻害剤

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250826

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250826